Comparison of Intralesional Sodium Stibogluconate versus Intralesional Meglumine Antimoniate for the Treatment of Leishmania major Cutaneous Leishmaniasis
DOI:
https://doi.org/10.2340/actadv.v104.35089Keywords:
leishmaniasis, Leishmania major, Leishmania Tropica, Pentavalent antimoniate, IntralesionalAbstract
Israel is endemic for Old-World cutaneous leishmaniasis. The most common species is Leishmania major. However, the available treatment options are limited. This study’s objective was to compare the authors’ experience with different antimony intralesional treatments of Leishmania major cutaneous leishmaniasis. A retrospective evaluation was undertaken for cases of Leishmania major cutaneous leishmaniasis treated by pentavalent antimony in a university-affiliated medical centre in Israel. The previous treatment of intralesional sodium stibogluconate (Pentostam®) was compared with the current treatment of meglumine antimoniate (Glucantime®). One hundred cases of cutaneous leishmaniasis were treated during the study period, of whom 33 were treated with intralesional sodium stibogluconate and 67 were treated with intralesional meglumine antimoniate. The patients were 78 males and 22 females, mean age 24 (range 10–67) and there was a total of 354 skin lesions. Within 3 months from treatment, 91% (30/33) of the intralesional sodium stibogluconate group and 88% (59/67) of the intralesional meglumine antimoniate group had complete healing of the cutaneous lesions after an average of 3 treatment cycles (non-statistically significant). In conclusion, the 2 different medications have the same efficacy and safety for treating cutaneous leishmaniasis. Pentavalent antimoniate intralesional infiltration treatment is safe, effective, and well tolerated with minimal side effects for Old-World cutaneous leishmaniasis.
Downloads
References
Jaffe CL, Baneth G, Abdeen ZA, Schlein Y, Warburg A. Leishmaniasis in Israel and the Palestinian authority. Trends Parasitol 2004; 20: 328-332.
https://doi.org/10.1016/j.pt.2004.05.001 DOI: https://doi.org/10.1016/j.pt.2004.05.001
Solomon M, Astman N, Warshavsky K, Barzilai A, Meningher T, Avni D, et al. Cutaneous leishmaniasis caused by leishmania infantum, Israel, 2018-2021. Emerg Infect Dis 2023; 29: 988-991.
https://doi.org/10.3201/eid2905.221812 DOI: https://doi.org/10.3201/eid2905.221812
Chance ML. New developments in the chemotherapy of leishmaniasis. Ann Trop Med Parasitol 1995; 89: 37-43.
https://doi.org/10.1080/00034983.1995.11813013 DOI: https://doi.org/10.1080/00034983.1995.11813013
Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez-Velez R, Weina P, et al. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis 2016; 63: e202-e264.
https://doi.org/10.1093/cid/ciw670 DOI: https://doi.org/10.1093/cid/ciw670
Solomon M, Baum S, Barzilai A, Pavlotsky F, Trau H, Schwartz E. Treatment of cutaneous leishmaniasis with intralesional sodium stibogluconate. J Eur Acad Dermatol Venereol 2009; 23: 1189-1192.
https://doi.org/10.1111/j.1468-3083.2009.03157.x DOI: https://doi.org/10.1111/j.1468-3083.2009.03157.x
Schonian G, Nasereddin A, Dinse N, Schweynoch C, Schallig HD, Presber W, et al. PCR diagnosis and characterization of Leishmania in local and imported clinical samples. Diagn Microbiol Infect Dis 2003; 47: 349-358.
https://doi.org/10.1016/S0732-8893(03)00093-2 DOI: https://doi.org/10.1016/S0732-8893(03)00093-2
Ben Salah A, Ben Messaoud N, Guedri E, Zaatour A, Ben Alaya N, Bettaieb J, et al. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med 2013; 368: 524-532.
https://doi.org/10.1056/NEJMoa1202657 DOI: https://doi.org/10.1056/NEJMoa1202657
El-On J, Halevy S, Grunwald MH, Weinrauch L. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. J Am Acad Dermatol 1992; 27: 227-231.
https://doi.org/10.1016/0190-9622(92)70175-F DOI: https://doi.org/10.1016/0190-9622(92)70175-F
Moosavi Z, Nakhli A, Rassaii S. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis. Int J Dermatol 2005; 44: 1064-1065.
https://doi.org/10.1111/j.1365-4632.2004.02597.x DOI: https://doi.org/10.1111/j.1365-4632.2004.02597.x
Brito NC, Rabello A, Cota GF. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: a systematic review. PLoS One 2017; 12: e0184777.
https://doi.org/10.1371/journal.pone.0184777 DOI: https://doi.org/10.1371/journal.pone.0184777
Shani-Adir A, Kamil S, Rozenman D, Schwartz E, Ramon M, Zalman L, et al. Leishmania tropica in northern Israel: a clinical overview of an emerging focus. J Am Acad Dermatol 2005; 53: 810-815.
https://doi.org/10.1016/j.jaad.2005.07.026 DOI: https://doi.org/10.1016/j.jaad.2005.07.026
Faghihi G, Tavakoli-kia R. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate. Clin Exp Dermatol 2003; 28: 13-16.
https://doi.org/10.1046/j.1365-2230.2003.01169.x DOI: https://doi.org/10.1046/j.1365-2230.2003.01169.x
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Michal Solomon, Ayelet Ollech , Felix Pavlotsky , Aviv Barzilai , Eli Schwartz, Sharon Baum , Nadav Astman
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
